Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Roche picks up European rights to diabetes implant

Will distribute Senseonics' Eversense CGM System in Germany, Italy and the Netherlands

Roche Eversense CGM Senseonics 

Roche's diabetes business has acquired distribution rights to an implantable long-term continuous glucose monitoring (CGM) system.

It will commercialise Senseonics' Eversense CGM system, selling the implant to diabetes patients and clinics in Germany, Italy and the Netherlands, with an options to expand the deal to further countries and products in the future.

The Eversense combines a small sensor that works for us to 90 days, a wearable and removable smart transmitter and mobile application, and seeks to replace the weekly CGM systems currently on the market.

The Eversense sensor is inserted below the patient's skin and uses flurorescence sensing technology to communicate with the smart transmitter, which then wirelessly sends blood glucose levels to the mobile app.

Tim Goodnow, CEO and president of Senseonics, said: “Together with Roche's market presence, and extensive sales and support network, we aim to deliver a truly innovative continuous, long-term glucose monitoring solution to millions of people with diabetes.”

Goodnow's company will retain responsibility for product development, regulatory approval, quality management, and manufacturing while Roche will take on sales, marketing, customer support and distribution activities in the agreement's territories.

The Maryland, US-based medical technology company's deal with Roche follows its agreement with Rubin Medical, which has the rights to market the Eversense system in Sweden, and follows soon after a tie-up between Medtronic and Qualcomm for a new range of diabetes sensors.

Meanwhile, Senseonics last month won a European Kitemark for the Eversense system, confirming it meets the European Commission's Essential Requirements of the Active Implantable Medical Device Directive.

2nd June 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics